| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,000 | 8,000 | 13:04 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 253 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 19.12.25 | ABL Diagnostics Informs the Market of a Non-Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger | 342 | Business Wire | The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.'s control over ABL Diagnostics at... ► Artikel lesen | |
| ABL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 05.12.25 | ABL Diagnostics S.A.: Information on a Temporary Transfer of ABL Diagnostics Shares | 324 | Business Wire | Regulatory News:
ABL Diagnostics S.A. (ISIN: FR001400AHX6, ticker: ABLD, listed on Euronext Paris) informs its shareholders and the market that a temporary transfer of 128,026 shares of the company... ► Artikel lesen | |
| 14.11.25 | ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market | 314 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio... ► Artikel lesen | |
| 22.10.25 | ABL Diagnostics SA: ABL Diagnostics - Announcement of a Second Agreement Between ABL SA and Alumni Capital | 253 | Business Wire | Regulatory News:
ISIN: FR001400AHX6 Euronext Paris
ABL Diagnostics SA (the "Company") (Paris:ABLD) informs the public that Advanced Biological Laboratories SA (ABL SA), its parent company, announced... ► Artikel lesen | |
| 16.10.25 | ABL Diagnostics SA: ABL Diagnostics: Switch to Continuous Trading on Euronext Paris as From November 3rd, 2025 | 320 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) announces the switch from a fixing-based trading mode to continuous trading as from November 3rd, 2025, in accordance... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | DAX-Konzern Siemens Healthineers legt Zahlen vor | Siemens Healthineers startet solide ins neue Geschäftsjahr und bestätigt den Jahresausblick, wird aber vom schwachen Diagnostikgeschäft in China gebremst. Der DAX-Konzern Siemens Healthineers ist mit... ► Artikel lesen | |
| THERMO FISHER | 460,70 | +0,35 % | Thermo Fisher to Close Franklin, Mass. Site, Cut Up to 80 Jobs | ||
| STRATEC | 21,050 | +0,72 % | Stratec: Experten rechnen mit konservativem Ausblick | Das vierte Quartal 2024 war bei Stratec besonders stark. Dieses Niveau dürfte die Gesellschaft Ende 2025 nicht erreicht haben. So rechnen die Analysten der Deutschen Bank auch mit einem Minus von 5... ► Artikel lesen | |
| UNIDOC HEALTH | 0,083 | -8,73 % | UniDoc stellt Installation des H3 Health Cube in Italien fertig | - Der KI-gestützte Health Cube steht
ab sofort den Patienten im Dorf Guardia Perticara in der italienischen Region Basilikata zur Verfügung.
VANCOUVER, British Columbia... ► Artikel lesen | |
| DIASORIN | 74,14 | +0,60 % | Milan: DiaSorin well in the green | ||
| BIOCARTIS | 0,260 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.01.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 21.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.01.2026ISIN NameBE0974281132 BIOCARTIS... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | ANALYSE-FLASH: Barclays senkt Carl Zeiss Meditec auf 'Equal Weight' | LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen |